Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MORF |
---|---|---|
09:32 ET | 1367 | 29.9 |
09:36 ET | 200 | 29.93 |
09:38 ET | 300 | 30.01 |
09:43 ET | 500 | 30.22 |
09:45 ET | 300 | 30.42 |
09:48 ET | 200 | 30.44 |
09:50 ET | 200 | 30.48 |
09:52 ET | 1000 | 30.69 |
09:54 ET | 1404 | 30.65 |
09:56 ET | 200 | 30.55 |
09:57 ET | 300 | 30.6 |
09:59 ET | 200 | 30.69 |
10:01 ET | 711 | 30.77 |
10:03 ET | 500 | 30.93 |
10:06 ET | 600 | 30.9 |
10:08 ET | 600 | 30.91 |
10:12 ET | 855 | 30.88 |
10:14 ET | 500 | 31.025 |
10:17 ET | 400 | 30.835 |
10:21 ET | 100 | 30.845 |
10:24 ET | 2392 | 31.02 |
10:30 ET | 305 | 31.15 |
10:33 ET | 272 | 31.05 |
10:35 ET | 100 | 30.96 |
10:39 ET | 100 | 31.12 |
10:48 ET | 400 | 31.155 |
10:50 ET | 100 | 31.225 |
10:51 ET | 212 | 31.15 |
10:53 ET | 400 | 31.1 |
10:57 ET | 100 | 31.075 |
11:02 ET | 629 | 31.06 |
11:08 ET | 100 | 30.98 |
11:09 ET | 200 | 31.05 |
11:18 ET | 266 | 30.98 |
11:20 ET | 200 | 30.95 |
11:24 ET | 300 | 31.02 |
11:26 ET | 200 | 31.15 |
11:31 ET | 200 | 31.0161 |
11:33 ET | 100 | 31.165 |
11:36 ET | 100 | 31.18 |
11:40 ET | 400 | 31.19 |
11:42 ET | 606 | 31.145 |
11:45 ET | 500 | 31.23 |
11:49 ET | 600 | 31.41 |
11:51 ET | 400 | 31.355 |
12:00 ET | 100 | 31.35 |
12:09 ET | 406 | 31.2 |
12:12 ET | 200 | 31.23 |
12:18 ET | 100 | 31.19 |
12:20 ET | 100 | 31.185 |
12:25 ET | 100 | 31.2 |
12:27 ET | 505 | 31.19 |
12:30 ET | 200 | 31.065 |
12:36 ET | 405 | 30.98 |
12:38 ET | 200 | 30.91 |
12:45 ET | 433 | 30.84 |
12:48 ET | 100 | 30.82 |
12:50 ET | 100 | 30.8 |
12:52 ET | 200 | 30.81 |
12:54 ET | 2328 | 30.76 |
12:57 ET | 210 | 30.775 |
01:01 ET | 610 | 30.83 |
01:06 ET | 300 | 30.8 |
01:08 ET | 1200 | 31.01 |
01:10 ET | 100 | 31.11 |
01:12 ET | 200 | 31.07 |
01:14 ET | 801 | 31.12 |
01:15 ET | 536 | 31.25 |
01:17 ET | 1300 | 31.33 |
01:19 ET | 800 | 31.4 |
01:24 ET | 300 | 31.46 |
01:26 ET | 800 | 31.38 |
01:28 ET | 100 | 31.37 |
01:30 ET | 620 | 31.12 |
01:35 ET | 737 | 31 |
01:39 ET | 500 | 31.07 |
01:46 ET | 311 | 31.02 |
01:48 ET | 100 | 30.94 |
01:50 ET | 150 | 30.9427 |
02:00 ET | 400 | 30.82 |
02:02 ET | 100 | 30.77 |
02:06 ET | 112 | 30.7 |
02:08 ET | 1179 | 30.755 |
02:09 ET | 100 | 30.84 |
02:13 ET | 410 | 30.88 |
02:24 ET | 500 | 30.9 |
02:29 ET | 300 | 30.8 |
02:31 ET | 100 | 30.86 |
02:36 ET | 921 | 30.89 |
02:38 ET | 800 | 31.06 |
02:42 ET | 300 | 31.095 |
02:45 ET | 200 | 31.0725 |
02:47 ET | 463 | 31.09 |
02:51 ET | 998 | 31.08 |
02:54 ET | 400 | 31.15 |
02:56 ET | 300 | 31.17 |
02:58 ET | 200 | 31.14 |
03:00 ET | 100 | 31.09 |
03:02 ET | 200 | 31.07 |
03:03 ET | 100 | 31.08 |
03:07 ET | 411 | 31.16 |
03:09 ET | 1300 | 31.04 |
03:12 ET | 500 | 31.125 |
03:18 ET | 600 | 31.12 |
03:20 ET | 100 | 31.16 |
03:21 ET | 500 | 31.17 |
03:23 ET | 8136 | 31.335 |
03:25 ET | 1206 | 31.31 |
03:27 ET | 1000 | 31.29 |
03:30 ET | 878 | 31.29 |
03:32 ET | 940 | 31.36 |
03:34 ET | 300 | 31.37 |
03:36 ET | 100 | 31.38 |
03:38 ET | 3200 | 31.28 |
03:39 ET | 700 | 31.33 |
03:41 ET | 223 | 31.31 |
03:43 ET | 300 | 31.29 |
03:45 ET | 700 | 31.3 |
03:48 ET | 400 | 31.35 |
03:50 ET | 2900 | 31.15 |
03:52 ET | 2566 | 31.02 |
03:54 ET | 2736 | 30.79 |
03:56 ET | 4000 | 30.73 |
03:57 ET | 7301 | 30.74 |
03:59 ET | 16230 | 30.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Morphic Holding Inc | 1.7B | -8.8x | --- |
Kura Oncology Inc | 1.7B | -10.0x | --- |
Edgewise Therapeutics Inc | 1.7B | -11.5x | --- |
Syndax Pharmaceuticals Inc | 1.6B | -6.1x | --- |
Sana Biotechnology Inc | 1.7B | -4.6x | --- |
Neumora Therapeutics Inc | 1.6B | -4.1x | --- |
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 50.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-3.49 |
Book Value | $14.01 |
P/E Ratio | -8.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.